Spots Global Cancer Trial Database for premenopausal
Every month we try and update this database with for premenopausal cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss | NCT00375505 | Breast Cancer | Zoledronic acid Placebo | 18 Years - | Novartis | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex | NCT00235937 | Breast Cancer | Anastrozole and... | 18 Years - | AstraZeneca | |
| Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer | NCT00976339 | Breast Cancer | Cholecalciferol | 21 Years - | Columbia University | |
| Comprehensive Lifestyle Change To Prevent Breast Cancer | NCT03448003 | Premenopausal | Cancer Preventi... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer | NCT00976339 | Breast Cancer | Cholecalciferol | 21 Years - | Columbia University | |
| Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | NCT01788839 | Breast Cancer Lymphoma Hodgkin's Lymph... | surveys Blood draw Transvaginal ul... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer | NCT01622361 | Breast Cancer | Adriamycin+Cycl... GnRHa with Tamo... | 20 Years - | Asan Medical Center | |
| RANKL Inhibition and Mammographic Breast Density | NCT04067726 | Dense Breasts | Denosumab Placebo Calcium Vitamin D3 Core needle bio... Blood draw | 40 Years - | Washington University School of Medicine | |
| Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer | NCT00976339 | Breast Cancer | Cholecalciferol | 21 Years - | Columbia University | |
| Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer | NCT03628066 | Breast Cancer | Letrozole Palbociclib Goserelin Oncotype DX Bre... | 18 Years - | NSABP Foundation Inc | |
| Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer | NCT03505736 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Premenopausal Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Adenosine Magnetic Resona... Regadenoson Stress Manageme... | - 55 Years | Wake Forest University Health Sciences | |
| Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid | NCT00295646 | Breast Cancer | tamoxifen anastrozole zoledronic acid goserelin | 19 Years - 59 Years | Austrian Breast & Colorectal Cancer Study Group | |
| Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer | NCT02344940 | Breast Cancer | Toremifene Tamoxifen | 18 Years - | Shanghai Jiao Tong University School of Medicine | |
| Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | NCT05645536 | Breast Cancer | TOL2506 Tamoxifen Letrozole table... Anastrozole Tab... Exemestane Tabl... | 18 Years - 51 Years | Tolmar Inc. | |
| Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer | NCT02308085 | Early Breast Ca... | Endocrine thera... | 18 Years - 42 Years | ETOP IBCSG Partners Foundation | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations | NCT02760849 | Deleterious BAR... Deleterious BRC... Deleterious BRC... Deleterious BRI... Deleterious EPC... Deleterious MLH... Deleterious MSH... Deleterious MSH... Deleterious PAL... Deleterious PMS... Deleterious RAD... Deleterious RAD... Hereditary Brea... Premenopausal | Laboratory Biom... Oophorectomy Quality-of-Life... Salpingectomy Salpingo-Oophor... | 30 Years - 50 Years | M.D. Anderson Cancer Center | |
| The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss | NCT00375505 | Breast Cancer | Zoledronic acid Placebo | 18 Years - | Novartis | |
| Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations | NCT02760849 | Deleterious BAR... Deleterious BRC... Deleterious BRC... Deleterious BRI... Deleterious EPC... Deleterious MLH... Deleterious MSH... Deleterious MSH... Deleterious PAL... Deleterious PMS... Deleterious RAD... Deleterious RAD... Hereditary Brea... Premenopausal | Laboratory Biom... Oophorectomy Quality-of-Life... Salpingectomy Salpingo-Oophor... | 30 Years - 50 Years | M.D. Anderson Cancer Center | |
| Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women | NCT01266213 | Metastatic Brea... Estrogen Recept... Breast Cancer N... | Fulvestrant plu... Anastrozole plu... Goserelin | - 55 Years | Samsung Medical Center | |
| Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | NCT04906395 | Breast Cancer | TOL2506 Tamoxifen Letrozole Table... Anastrozole Tab... Exemestane Tabl... | 18 Years - 49 Years | Tolmar Inc. | |
| Comprehensive Lifestyle Change To Prevent Breast Cancer | NCT03448003 | Premenopausal | Cancer Preventi... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer | NCT03351062 | Breast Cancer F... | Tamoxifen Toremifene | 18 Years - 50 Years | Chinese Anti-Cancer Association | |
| Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | NCT05645536 | Breast Cancer | TOL2506 Tamoxifen Letrozole table... Anastrozole Tab... Exemestane Tabl... | 18 Years - 51 Years | Tolmar Inc. | |
| Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer | NCT00201851 | Breast Cancer | Tamoxifen Surgery: Oophor... | 18 Years - 50 Years | International Breast Cancer Research Foundation | |
| HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. | NCT00412022 | Breast Cancer | tamoxifen triptorelin letrozole zoledronic acid | 18 Years - | National Cancer Institute, Naples | |
| RANKL Inhibition and Breast Tissue Biomarkers | NCT03629717 | Breast Cancer P... Mammographic De... | Ultrasound-guid... Denosumab Blood draw Calcium Vitamin D | 35 Years - | Washington University School of Medicine | |
| PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer | NCT02917005 | Metastatic Brea... | Palbociclib Exemestane Goserelin | 18 Years - | Africa Middle East Cancer Intergroup | |
| Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer | NCT02344940 | Breast Cancer | Toremifene Tamoxifen | 18 Years - | Shanghai Jiao Tong University School of Medicine | |
| Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | NCT04906395 | Breast Cancer | TOL2506 Tamoxifen Letrozole Table... Anastrozole Tab... Exemestane Tabl... | 18 Years - 49 Years | Tolmar Inc. | |
| Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer | NCT03822468 | Breast Cancer | Ribociclib Anastrozole Letrozole Goserelin | 18 Years - | Novartis | |
| Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer | NCT02344940 | Breast Cancer | Toremifene Tamoxifen | 18 Years - | Shanghai Jiao Tong University School of Medicine | |
| Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer | NCT03505736 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Premenopausal Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Adenosine Magnetic Resona... Regadenoson Stress Manageme... | - 55 Years | Wake Forest University Health Sciences | |
| A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss | NCT00333229 | Primary Hormone... | Zoledronic Acid Placebo | 18 Years - | Novartis | |
| Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer | NCT01622361 | Breast Cancer | Adriamycin+Cycl... GnRHa with Tamo... | 20 Years - | Asan Medical Center | |
| Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | NCT01788839 | Breast Cancer Lymphoma Hodgkin's Lymph... | surveys Blood draw Transvaginal ul... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| RANKL Inhibition and Breast Tissue Biomarkers | NCT03629717 | Breast Cancer P... Mammographic De... | Ultrasound-guid... Denosumab Blood draw Calcium Vitamin D | 35 Years - | Washington University School of Medicine | |
| Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | NCT01788839 | Breast Cancer Lymphoma Hodgkin's Lymph... | surveys Blood draw Transvaginal ul... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss | NCT00333229 | Primary Hormone... | Zoledronic Acid Placebo | 18 Years - | Novartis | |
| A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer | NCT05910294 | Improve Sexual ... Improve Vulvova... | questionnaires moisturizers moisturizers | 18 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
